Literature DB >> 25339217

Clinical response to bevacizumab in schwannomatosis.

Jaishri Blakeley1, Karisa C Schreck2, D Gareth Evans1, Bruce R Korf1, David Zagzag1, Matthias A Karajannis1, Amanda L Bergner1, Allan J Belzberg1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25339217      PMCID： PMC4248457          DOI： 10.1212/WNL.0000000000000997

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  7 in total

Review 1.  Diagnostic criteria for schwannomatosis.

Authors:  M MacCollin; E A Chiocca; D G Evans; J M Friedman; R Horvitz; D Jaramillo; M Lev; V F Mautner; M Niimura; S R Plotkin; C N Sang; A Stemmer-Rachamimov; E S Roach
Journal:  Neurology       Date:  2005-06-14       Impact factor: 9.910

2.  Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis.

Authors:  K D Hadfield; W G Newman; N L Bowers; A Wallace; C Bolger; A Colley; E McCann; D Trump; T Prescott; D G R Evans
Journal:  J Med Genet       Date:  2008-02-19       Impact factor: 6.318

3.  Evidence of a four-hit mechanism involving SMARCB1 and NF2 in schwannomatosis-associated schwannomas.

Authors:  Roberta Sestini; Costanza Bacci; Aldesia Provenzano; Maurizio Genuardi; Laura Papi
Journal:  Hum Mutat       Date:  2008-02       Impact factor: 4.878

4.  Immunohistochemical analysis supports a role for INI1/SMARCB1 in hereditary forms of schwannomas, but not in solitary, sporadic schwannomas.

Authors:  Sushama Patil; Arie Perry; Mia Maccollin; Shumin Dong; Rebecca A Betensky; Tu-Hsueh Yeh; David H Gutmann; Anat O Stemmer-Rachamimov
Journal:  Brain Pathol       Date:  2008-04-15       Impact factor: 6.508

5.  Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.

Authors:  Scott R Plotkin; Anat O Stemmer-Rachamimov; Fred G Barker; Chris Halpin; Timothy P Padera; Alex Tyrrell; A Gregory Sorensen; Rakesh K Jain; Emmanuelle di Tomaso
Journal:  N Engl J Med       Date:  2009-07-08       Impact factor: 91.245

6.  Vascular endothelial growth factor signaling in injured nerves underlies peripheral sensitization in neuropathic pain.

Authors:  Norikazu Kiguchi; Yuka Kobayashi; Yui Kadowaki; Yohji Fukazawa; Fumihiro Saika; Shiroh Kishioka
Journal:  J Neurochem       Date:  2013-12-04       Impact factor: 5.372

7.  Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors.

Authors:  Hon Kit Wong; Johanna Lahdenranta; Walid S Kamoun; Annie W Chan; Andrea I McClatchey; Scott R Plotkin; Rakesh K Jain; Emmanuelle di Tomaso
Journal:  Cancer Res       Date:  2010-04-20       Impact factor: 12.701
  7 in total
  12 in total

1.  Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models.

Authors:  Yingchao Zhao; Pinan Liu; Na Zhang; Jie Chen; Lukas D Landegger; Limeng Wu; Fu Zhao; Yanxia Zhao; Yanling Zhang; Jing Zhang; Takeshi Fujita; Anat Stemmer-Rachamimov; Gino B Ferraro; Hao Liu; Alona Muzikansky; Scott R Plotkin; Konstantina M Stankovic; Rakesh K Jain; Lei Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-09       Impact factor: 11.205

Review 2.  Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis.

Authors:  Jaishri O Blakeley; Scott R Plotkin
Journal:  Neuro Oncol       Date:  2016-02-06       Impact factor: 12.300

3.  Schwannomatosis patient who was followed up for fifteen years: A case report.

Authors:  Kai Li; Si-Jing Liu; Huai-Bo Wang; Chang-Yu Yin; Yong-Sheng Huang; Wei-Tao Guo
Journal:  World J Clin Cases       Date:  2022-07-16       Impact factor: 1.534

4.  Benign Hand Tumors (Part II): Soft Tissue Tumors.

Authors:  Jonathan Lans; Kai-Lou C Yue; René M Castelein; David I Suster; G Petur Nielsen; Neal C Chen; Santiago A Lozano-Calderon
Journal:  Hand (N Y)       Date:  2020-07-15

5.  Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model.

Authors:  Xing Gao; Yingchao Zhao; Anat O Stemmer-Rachamimov; Hao Liu; Peigen Huang; ShanMin Chin; Martin K Selig; Scott R Plotkin; Rakesh K Jain; Lei Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-09       Impact factor: 11.205

6.  Bevacizumab for Treatment-Refractory Pain Control in Neurofibromatosis Patients.

Authors:  Xu W Linda; Lawrence D Recht
Journal:  Cureus       Date:  2016-12-18

7.  The Secretomes of Painful Versus Nonpainful Human Schwannomatosis Tumor Cells Differentially Influence Sensory Neuron Gene Expression and Sensitivity.

Authors:  Kimberly Laskie Ostrow; Katelyn J Donaldson; Michael J Caterina; Allan Belzberg; Ahmet Hoke
Journal:  Sci Rep       Date:  2019-09-11       Impact factor: 4.379

8.  A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2.

Authors:  Ryota Tamura; Masato Fujioka; Yukina Morimoto; Kentaro Ohara; Kenzo Kosugi; Yumiko Oishi; Mizuto Sato; Ryo Ueda; Hirokazu Fujiwara; Tetsuro Hikichi; Shinobu Noji; Naoki Oishi; Kaoru Ogawa; Yutaka Kawakami; Takayuki Ohira; Kazunari Yoshida; Masahiro Toda
Journal:  Nat Commun       Date:  2019-12-17       Impact factor: 14.919

Review 9.  Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis.

Authors:  Ryota Tamura
Journal:  Int J Mol Sci       Date:  2021-05-29       Impact factor: 5.923

10.  Multiparametric whole-body anatomic, functional, and metabolic imaging characteristics of peripheral lesions in patients with schwannomatosis.

Authors:  Shivani Ahlawat; Asad Baig; Jaishri O Blakeley; Michael A Jacobs; Laura M Fayad
Journal:  J Magn Reson Imaging       Date:  2016-03-17       Impact factor: 5.119
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.